Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 11/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 10/20 | 0.50 |
| ▸ | DHODH | Q02127 | 2/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4361087 | 0.91 | IGF2BP2 (0.56) | AKR1C2AKR1C3DHODHAKR1C1IGF2BP2 | |
| SCHEMBL4217609 | 0.90 | DHODH (0.52) | AKR1C2AKR1C3DHODHIGF2BP2 | |
| SCHEMBL4226484 | 0.87 | XDH (0.54) | AKR1C2AKR1C3DHODHPPARAXDH | |
| SCHEMBL4225674 | 0.85 | AKR1C3 (0.71) | AKR1C2AKR1C3XDHSLC22A12 | |
| SCHEMBL4217072 | 0.85 | AKR1C3 (0.47) | AKR1C2AKR1C3DHODHIDO1TDO2 | |
| SCHEMBL4217365 | 0.85 | AKR1C3 (0.47) | AKR1C2AKR1C3DHODHPPARAIDO1 | |
| SCHEMBL4217075 | 0.85 | AKR1C3 (0.47) | AKR1C2AKR1C3DHODHIDO1TDO2 | |
| SCHEMBL4220015 | 0.84 | ACLY (0.55) | AKR1C2AKR1C3XDHSLC22A12 | |
| SCHEMBL4215664 | 0.83 | ACLY (0.52) | AKR1C2AKR1C3XDHSLC22A12 | |
| SCHEMBL12075518 | 0.83 | DHODH (0.59) | AKR1C2AKR1C3DHODHAKR1C1IGF2BP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8327467-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1860098-B1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1860098-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP11, MMP3 | AKR1C2 287/4885AKR1C3 105/4885DHODH 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.